Aliya Khan is a Professor of Clinical Medicine, Divisions of Endocrinology and Metabolism and Geriatrics at McMaster University and Director of the Calcium Disorders Clinic at McMaster University Medical Centre. She is also the Director of the Fellowship program in Metabolic Bone Disease at McMaster University.

She graduated from the University of Ottawa Medical School with Honors at the age of 22 in the top quarter of her class. She trained in Internal Medicine, Geriatric Medicine and Endocrinology at the University of Toronto and also completed a research fellowship in Calcium and Metabolic Bone disorders at the University of Toronto.

She has over 200 scientific publications on osteoporosis and parathyroid disease as well as numerous book chapters. She is the Editor of the Handbook of Parathyroid Diseases as well as the Co-Editor of the Textbook Bone Metabolism, Parathyroid Gland and Calciotropic Hormones.

Dr. Khan is a member of the Canadian Society of Endocrinology and Metabolism Guidelines committee. She is the founding co-chair of Canadian Endocrine Update. Dr. Khan serves as a peer reviewer for the College of Physicians and Surgeons of Ontario for Endocrinology and Metabolism. She led the development of point of care quality improvement tools for the diagnosis and management of endocrine disorders.

Dr. Khan co-chaired the 3rd and 4th International Workshops on Primary Hyperparathyroidism proceedings published in JCEM in 2009 and 2014, respectively. Dr. Khan led the development of the international standards of care for hypoparathyroidism published in 2019.

Dr. Khan led the 1st international study on the use of alendronate in primary hyperparathyroidism as well as the phase 3 trial on the use of cinacalcet in primary hyperparathyroidism. She is currently investigating the use of various PTH molecules in the management of hypoparathyroidism in phase 1 and phase 2 clinical trials. She is the principal investigator of the Canadian National Hypoparathyroidism Registry. She has been involved as a national co-investigator in evaluating bisphosphonates, teriparatide, raloxifene, denosumab, romosozumab as well as abaloparatide in the management of osteoporosis.

Dr. Khan led the development of the Canadian position paper on the diagnosis and management of hypophosphatasia. Dr Khan is the Chair of the Rapid Response Committee of Osteoporosis Canada as well as the Co-chair of the Knowledge Translation committee of Osteoporosis Canada. She is a Scientific Advisor of the International Osteoporosis Foundation and Chair of the International Osteonecrosis of the Jaw Task Force. She led the development of the first international position paper on the diagnosis, prevention, and management of osteonecrosis of the jaw published in 2015 in JBMR.

She formed the Canadian Panel of the International Society of Clinical Densitometry (ISCD) and was a board member of the ISCD as well as the past Chair of the Credentials committee of the ISCD. She led the development of the Canadian Standards for the diagnosis of osteoporosis in men, women, and children.

In 2019 Dr. Khan was asked to serve as the Canadian Ambassador for the American Society of Bone and Mineral Research. She is also serving on the Professional Practice Committee of the ASBMR.

Dr. Khan has received numerous national and international awards including the International Clinician Instructor of the Year 2011 award by the International Society of Clinical Densitometry. The Queen’s Diamond Jubilee Medal for 2012 for excellence in clinical care, research and teaching as well as the International Hypoparathyroidism Award for 2014 and the International Osteoporosis Foundation award for publishing excellence in 2017. In 2019 she was recognized as being in the top 0.1% of the world experts in hyperparathyroidism by Expertscape. In 2020 Dr. Khan was awarded the Osteoporosis Canada Lindy Fraser Award in recognition of her outstanding contributions to the field of osteoporosis research and education.